---
title: "Halozyme Stock Slides, European Patent Fight With Merck Spurs Fresh Pressure"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306160621.md"
description: "Halozyme Therapeutics (HALO) shares dropped 4.19% to $91.79 after a German court overturned a preliminary injunction blocking Merck’s Keytruda SC launch. Halozyme plans to file an infringement lawsuit in Germany for permanent relief, citing disappointment with the decision. This legal setback adds pressure amid broader market weakness and recent analyst downgrades by Morgan Stanley and Leerink Partners, though the stock retains strong momentum and quality scores."
datetime: "2026-11-19T18:15:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306160621.md)
  - [en](https://longbridge.com/en/news/306160621.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306160621.md)
generator: "portal-rs"
---

# Halozyme Stock Slides, European Patent Fight With Merck Spurs Fresh Pressure

**Halozyme Therapeutics, Inc.** (NASDAQ:HALO) shares are trading lower on Thursday as investors digest an update on its European patent fight with Merck, while risk appetite is already soft with the S&P 500 down 0.31% and Healthcare sliding 1.82% (the weakest sector today).

## HALO Stock Drops After Merck Keytruda SC Patent Update

Halozyme said a German Higher Regional Court overturned a preliminary injunction that had halted Merck’s Keytruda SC launch in Germany, and the company plans to immediately file an infringement lawsuit in Germany seeking permanent relief.

The company also pointed to an October 2026 Dutch patent court decision that prohibited manufacturing, offering, marketing, using, importing, or holding Keytruda SC stock in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands.

 **Read Also: Halozyme Therapeutics Projects Sustained Growth Well Into 2040** 

“We are disappointed that the Higher Regional Court overturned the preliminary injunction halting the launch of Keytruda SC in Germany. We disagree with the decision and will immediately file an infringement lawsuit against Merck in Germany seeking permanent relief, which is not precluded by today’s decision,” said **Mark Snyder**, Chief Legal Officer of Halozyme.

**Analyst Consensus & Recent Actions:** The stock carries a Buy rating with an average price forecast of $118.63. Recent analyst moves include:

-   **Morgan Stanley**: Downgraded to Equal-Weight (Raises Price Forecast to $109.00) (Nov. 11)
-   **Leerink Partners**: Downgraded to Market Perform (Raises Price Forecast to $117.00) (Nov. 6)
-   **Citizens**: Market Outperform (Raises Price Forecast to $149.00) (Nov. 6)

## How HALO Ranks On Momentum, Quality And Value

Below is the Benzinga Edge scorecard for Halozyme Therapeutics, highlighting its strengths and weaknesses compared to the broader market:

-   **Momentum**: Strong (Score: 89.95) — Despite today’s drop, the stock’s broader performance profile still screens as market-leading on momentum factors.
-   **Quality**: Strong (Score: 97.78) — The scorecard is flagging strong underlying business quality versus the broader market.
-   **Value**: Weak (Score: 18.9) — Valuation screens as less compelling, which can make the stock more sensitive when headlines hit.

## Top ETFs Holding Halozyme Therapeutics (HALO)

-   **First Trust NYSE Arca Biotechnology Index Fund** (NYSE:FBT): 4.84% Weight
-   **Invesco S&P MidCap 400 GARP ETF** (NYSE:GRPM): 3.22% Weight
-   **Congress SMid Growth ETF** (NYSE:CSMD): 4.29% Weight

**HALO Stock Price Activity:** Halozyme Therapeutics shares were down 4.19% to $91.79 at the time of publication on Thursday, according to Benzinga Pro data.

 **Read Also: Satya Nadella Once Told Bill Gates 'Founders Also Die,' Says Jensen Huang Built Nvidia's 'Institutional Strength' to Thrive Beyond Him** 

*Image via Shutterstock*

### Related Stocks

- [HALO.US](https://longbridge.com/en/quote/HALO.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Merck (MRK) Pairs AI Drug Discovery Deal With Nemtabrutinib Phase 3 Exit](https://longbridge.com/en/news/306165192.md)
- [Halozyme Therapeutics President and CEO Helen Torley Reports Sale of $6 Million in Common Shares](https://longbridge.com/en/news/305745734.md)
- [What Could Merck (MRK) Gain From Two Positive CHMP Opinions In Europe?](https://longbridge.com/en/news/305540326.md)
- [Halozyme Therapeutics Director Matthew L. Posard Reports Sale of 5,000 Common Shares for $482,146.60](https://longbridge.com/en/news/306031595.md)
- [Merck's drug prolongs survival in advanced stomach, esophageal cancers in trial](https://longbridge.com/en/news/306275909.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**